{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Ethics, Cost, and Evidence Surrounding Current Pharmacological Treatment of Hepatitis C Infection

Activity Steps

Purpose of Activity

To provide information on the ethics and cost of the pharmacological treatment of hepatitis C virus (HCV) infection.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify a mode of transmission and risk factors for and risks from HCV infection.
  2. Examine the costs of pharmacological treatment of HCV infection and factors affecting the success or failure of treatment.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • KY-BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.







Test Code: CNS0717
Published: Jul/Aug 2017
Expires: 12/31/2026
Required Passing Score: 7/10 (70%)
Authors: Patricia Anne O'Malley, PhD, RN, CNS
Specialties: Infectious Diseases
Topics: Hepatitis C